Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
C-MER Eye Care Holdings Limited ( (HK:3309) ) has issued an update.
C-MER Medical Holdings Limited announced a significant collaboration involving its subsidiary, Health Hope Pharma Limited (HHP), which has entered into a global licensing agreement with Gilead Sciences and Hanmi Pharm for encequidar, a P-glycoprotein inhibitor in virology. This agreement grants Gilead exclusive global rights to encequidar, with HHP receiving an upfront payment and potential future financial benefits. This strategic move aligns with C-MER’s goal to leverage innovative drug projects, potentially impacting its market position in oncology and virology.
The most recent analyst rating on (HK:3309) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on C-MER Eye Care Holdings Limited stock, see the HK:3309 Stock Forecast page.
More about C-MER Eye Care Holdings Limited
C-MER Medical Holdings Limited operates in the medical industry, focusing on innovative drug projects primarily in oncology and ophthalmology. The company, through its joint venture HHP, is involved in developing oral anti-cancer drug programs and holds a portfolio of relevant patents. HHP is a clinical-stage biotech company with operations in Hong Kong, the U.S., and the UK.
Average Trading Volume: 1,037,401
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.36B
For a thorough assessment of 3309 stock, go to TipRanks’ Stock Analysis page.